Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy

Show other versions (1)

Bibliographic Details
Main Author:	Baptist Gallwitz
Format:	Article
Language:	English
Published:	SAGE Publishing 2012-01-01
Series:	Clinical Medicine Insights: Endocrinology and Diabetes
Online Access:	http://la-press.com/linagliptina-novel-dipeptidyl-peptidase-inhibitor-for-type-2-diabetes--a2986

Similar Items

Linagliptin–-A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
by: Baptist Gallwitz
Published: (2012-01-01)

Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors
by: Baptist Gallwitz
Published: (2013-06-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
by: Gallwitz B
Published: (2013-01-01)

Effect of Dipeptidyl Peptidase-4 Inhibitor, Linagliptin on Vascular Thrombosis and Inflammation in Human Endothelial Cell
by: Hsiang-Yu Wang, et al.
Published: (2019)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
by: Yuriko Nakaoku, et al.
Published: (2019-05-01)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
by: Capuano A, et al.
Published: (2013-09-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose.
by: Salheen M Salheen, et al.
Published: (2015-01-01)

The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation.
by: Makoto Ide, et al.
Published: (2020-01-01)

Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
by: Yun-Mi Jang, et al.
Published: (2011-04-01)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
by: Vladimer Darsalia, et al.
Published: (2019-05-01)

Dipeptidyl-Peptidase IV inhibitors and glycemic control in type 2 Diabetes Mellitus
by: Lokendra Bahadur Sapkota, et al.
Published: (2016-03-01)

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
by: Bernd Richter, et al.
Published: (2008-08-01)

Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin
by: Gallwitz B
Published: (2015-05-01)

Vipidia is a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
by: T. B. Morgunova, et al.
Published: (2015-12-01)

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4
by: Takehiro Yamaguchi, et al.
Published: (2019-02-01)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
by: Awadhesh Kumar Singh
Published: (2014-01-01)

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
by: Erna Kristin
Published: (2016-12-01)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Hiroki Esaki, et al.
Published: (2017-11-01)

Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
by: Mary Elizabeth Cox, et al.
Published: (2010-01-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans
by: Sri Nagarjun Batchu, et al.
Published: (2020-08-01)

Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
by: Cristina Mega, et al.
Published: (2017-01-01)

The role of dipeptidyl peptidase - 4 inhibitors in diabetic kidney disease
by: Usha ePanchapakesan, et al.
Published: (2015-08-01)

Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
by: Baptist Gallwitz
Published: (2007-05-01)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
by: Lin YH, et al.
Published: (2019-12-01)

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Shusuke Yagi, et al.
Published: (2015-08-01)

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
by: Pegah Yousefzadeh, et al.
Published: (2013-01-01)

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
by: Tzu-Lin Yang, et al.
Published: (2016-04-01)

Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
by: Xin Wei, et al.
Published: (2021-08-01)

The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
by: Aleksander Sergeevich Ametov, et al.
Published: (2015-07-01)

Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
by: A S Ametov, et al.
Published: (2014-08-01)

Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
by: Eugene Yu-Chuan Kang, et al.
Published: (2021-06-01)

Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
by: Deep Dutta, et al.
Published: (2021-04-01)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
by: Na-Hyung Kim, et al.
Published: (2014-01-01)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
by: A S Ametov, et al.
Published: (2013-01-01)

Retrospective Study of Dipeptidyl Peptidase-IV Inhibitor of Anti-diabetic Agents
by: Chia-Lung Chuang, et al.
Published: (2014)

All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes
by: Fu-Shun Yen, et al.
Published: (2019-01-01)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
by: Permsuwan U, et al.
Published: (2016-09-01)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin
by: Peng X, et al.
Published: (2016-08-01)

Incident cancer risk in dipeptidyl peptidase-4 inhibitor-treated patients with type 2 diabetes mellitus
by: Choi YJ, et al.
Published: (2019-08-01)

Cannot write session to /tmp/vufind_sessions/sess_qnmun1vo66rd0d76jps3numn72